AVR — Anteris Technologies Global Corp.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 2011514 ·
Last close
$5.32
Market Cap
$518.67M
52W High
$11.06
52W Low
$3.30
ADV30
1,492,264
Next earnings
2026-11-12
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 519,000 393,000 -29,841,000 -26,826,000 262,465,000 232,299,000 35,411,000
Jun 2026 1,009,000 776,000 -30,997,000 -29,094,000 272,507,000 256,867,000 20,837,000
Mar 2026 494,000 380,000 -24,007,000 -23,024,000 294,722,000 282,699,000 16,311,000
Dec 2025 310,000 219,000 -29,207,000 -29,202,000 22,997,000 — 23,250,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-90,900,000
Investing CF
$-2,622,000
Financing CF
$320,752,000
CapEx
$-2,622,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.48
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-449,476,000
Inventory
$0
Receivables
$220,000
ST Investments
—
EBIT TTM
$-107,119,000
Pretax Income TTM
$-107,304,000
Interest Exp TTM
$185,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,332,000
EBITDA
$-111,993,000
Free Cash Flow
$-59,060,876
Enterprise Value
$312,514,400
Total Cash
$232,299,008
Total Debt
$16,116,000
Shares Out
97,493,429
Trailing EPS
$-1.60
Book Value
$2.33
ROE
-93.3%
ROA
-50.5%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,913,000 -94,136,000 -94,144,000 22,997,000 23,250,000 -93,000 -77,803,000
Dec 2024 2,703,000 -77,329,000 -76,291,000 80,699,000 18,017,000 62,761,000 -61,241,000
Dec 2023 2,800,884 -48,122,276 -45,874,304 31,136,343 11,608,797 19,486,580 —
Dec 2022 3,122,608 -32,236,540 -30,164,606 15,973,036 6,980,985 8,992,051 —
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$2,242,000
NetIncome TTM
$-103,564,000
OpCashFlow TTM
—
Assets (Latest)
$272,507,000
Forward EPS
$-1.11

Max Pain — expiry 2027-02-19

max pain strike: $5.00 · spot: $5.21 · call oi: 1,934 · put oi: 360
Expected Move to 2027-02-19: ±$2.35 (45.11%) — implied range $2.86 – $7.56 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
RCEL AVITA Medical, Inc. $495.50M $15.77 —
OBIO Orchestra BioMed Holdings, Inc. $548.57M $6.97 —
AVHHL AVITA Medical, Inc. $549.85M $3.50 —
CARL CARLSMED, INC. $486.15M $17.74 —
ANGO ANGIODYNAMICS INC $483.21M $11.49 —

News headlines (Yahoo Finance, 1h cache)

Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
2026-11-16 11:00 · Yahoo
Small cap Snapshot: Anteris expands trial, PilbaraGold expands mineralsiation and more...
2026-11-11 04:51 · Yahoo
Anteris Technologies advances PARADIGM trial and manufacturing scale-up in third quarter
2026-11-10 23:44 · Yahoo
Anteris Technologies Announces Results for the Third Quarter of 2026
2026-11-10 22:28 · Yahoo
Anteris Technologies reports strong 30-day DurAVR heart valve outcomes from EMBARK Study
2026-11-01 23:05 · Yahoo
Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data
2026-11-01 22:58 · Yahoo
Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026
2026-11-01 19:59 · Yahoo
Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026
2026-10-27 10:00 · Yahoo
Anteris Technologies secures German clearance to expand PARADIGM heart valve trial
2026-10-20 02:02 · Yahoo
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
2026-10-20 01:12 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.